We’re pleased to announce the FDA has accepted our filing related to #RSV disease. Learn more: go.merck.com/~dti
We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only.
FLS: merck.us/3TKXNuZ
- Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it
- We’re presenting new data at AIDS 2026, in collaboration with @GileadSciences, from our Phase 3 trials of an investigational, once-weekly oral #HIV treatment for adults with virologically suppressed HIV. Learn more: go.merck.com/~lkm


